Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

NCT03588923 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

HCV Infection

Interventions

DRUG: SH229
DRUG: Placebos
DRUG: SH229
DRUG: Placebos
DRUG: SH229
DRUG: Placebos

Sponsor

Nanjing Sanhome Pharmaceutical, Co., Ltd.